CD274 and cancer: As the result of the ICI therapy benefit predicted by TIDE is inconsistent with the result of the antitumor immune response in the MRGPI subgroups, we further estimated the prognostic value of the MRGPI in two cancer cohorts that had received anti-PD-L1 therapy.